Covid-19 vaccine proves 90% effective
The developers - Pfizer and BioNTech - say their vaccine has been tested on 43,500 people in six countries and no safety concerns have been raised. The companies plan to apply for emergency approval to use the vaccine by the end of the month.
A vaccine is regarded as the best way to control the virus. There are around a dozen in the final stages of testing - known as a phase 3 trial - but this is the first to show any results. It uses a completely experimental approach - that involves injecting part of the virus's genetic code - in order to train the immune system.
Two doses, three weeks apart, are needed. The trials - in US, Germany, Brazil, Argentina, South Africa and Turkey - show 90% protection is achieved seven days after the second dose.
Pfizer believes it will be able to supply 50-million doses by the end of this year, and around 1.3bn by the end of 2021.
Related
Viatris fined in Morocco over merger notification, sources say 22 Nov 2024 African drug supply chain gets smarter with IBM-powered AI platform 14 Nov 2024 Leadership shakeup at Moderna ahead of major vaccine rollouts 8 Nov 2024 Legal and regulatory insights into South Africa’s growing medical cannabis market 2 Oct 2024 BioNTech gets $145m funding for African vaccine plants 30 May 2024
